Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Honored to present at ESMO Annual Meeting Berlin Young Oncologists Clinical Case Discussions!
Date:Oct 18 | 09:00-10:00 CEST
Location: Erfurt Auditorium, Berlin
Topic: Using ESCAT II/III alterations when standard options are exhausted
Joining brilliant colleagues Drs. Myrto Moutafi and Maximilian Kloft for interactive case discussions. Young oncologists – bring your challenging cases!
Scientific co-chairs Drs. Toni Choueiri Myriam Chalabi
This session is particularly close to my heart because:
- It bridges the gap between genomic findings and clinical reality
- It empowers young oncologists to think beyond conventional treatment algorithms
To all young oncologists attending ESMO 2025: This is YOUR session.”
More posts featuring ESMO25.